Altman Daniel, Granath Fredrik, Mattiasson Anders, Falconer Christian
Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden.
Int Urogynecol J Pelvic Floor Dysfunct. 2009 Nov;20(11):1285-91. doi: 10.1007/s00192-009-0957-z. Epub 2009 Jul 28.
Nationwide use and costs of anticholinergic drug for overactive bladder are unknown.
We performed a nationwide study based on the Swedish Register on Prescribed Pharmaceuticals.
From 2000 to 2007, there was a 68.8% increase in dispensed anticholinergic drugs in a population of 9 million. More than 93 million DDDs (calculated average maintenance dose per day) of anticholinergic drugs were dispensed corresponding to an overall DDD/TID (DDD per 1,000 inhabitants per day) of 3.5 per 1,000 persons per year. Approximately two thirds of anticholinergic drugs were prescribed to women, regardless of drug type. In 2007, the cost for anticholinergic drugs was 22 million
In this nationwide study, there was a 70% increased rate of expedited prescriptions of anticholinergic drugs for the treatment of overactive bladder in a relatively stable population.
抗胆碱能药物在治疗膀胱过度活动症方面的全国性使用情况及成本尚不清楚。
我们基于瑞典处方药登记系统开展了一项全国性研究。
2000年至2007年期间，在900万人口中，抗胆碱能药物的配药量增加了68.8%。抗胆碱能药物的配药量超过9300万个限定日剂量（DDD，即计算得出的每日平均维持剂量），相当于每年每1000人中有3.5个DDD/TID（每1000名居民每天的DDD数）。无论药物类型如何，约三分之二的抗胆碱能药物是开给女性的。2007年，抗胆碱能药物的成本为2200万欧元，其中托特罗定占70.8%。索利那新和达非那新在上市后其DDD/TID稳步上升。
在这项全国性研究中，在相对稳定的人群中，用于治疗膀胱过度活动症的抗胆碱能药物加急处方率上升了70%。
